Andrew Hall
Chief Executive Officer bei IMV INC.
Vermögen: 12 $ am 31.12.2023
Profil
Andrew Hall is currently the Chief Executive Officer & Director at IMV, Inc. He previously worked as an Executive Director of Business Development at Celgene Corp.
and as an Executive Director of Global Women's Health at Merck & Co., Inc. Mr. Hall completed his undergraduate degree at the University of Melbourne and his graduate degree at RMIT University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IMV INC.
0,05% | 20.03.2023 | 6 100 ( 0,05% ) | 12 $ | 31.12.2023 |
Aktive Positionen von Andrew Hall
| Unternehmen | Position | Beginn |
|---|---|---|
| IMV INC. | Chief Executive Officer | 04.08.2021 |
Ehemalige bekannte Positionen von Andrew Hall
| Unternehmen | Position | Ende |
|---|---|---|
| MERCK & CO., INC. | Corporate Officer/Principal | - |
| CELGENE | Corporate Officer/Principal | - |
Ausbildung von Andrew Hall
| University of Melbourne | Undergraduate Degree |
| RMIT University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| IMV INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
